Arjen Lindenholz

178 CHAPTER 7 Control ID Occlusion site NIHSS alteplase Symptoms < 6 hr Occlusion (retrospective) Time symptom onset – MRI (days) Ipsilateral enhancing foci Contralateral enhancing foci 20 ICA left 9 N N N 6 ICA-C - 21 MCA left 21 N N N 4 - - 22 ICA right 4 Y Y Y 7 ICA-C 2x, M1-E, M2-E - 23 ICA left 5 N N N 7 - ICA-E 24 MCA left 4 N N Y 3 ICA-C - 25 MCA left 4 Y Y N 4 M1-E 2x - 26 MCA right 3 N Y N 5 - - 27 MCA right 5 N Y Y 4 - - 28 MCA left 4 Y Y N 6 ICA-E M1-E 29 MCA right 10 Y Y Y 7 - M2-E 30 MCA left 3 Y Y N 10 ICA-E, M1-E ICA-E 2x 31 MCA right 10 N N N 40 ICA-C ICA-C 32 MCA left 2 Y Y N 29 - - 33 MCA left 10 N Unknown N 65 ICA-E, M1-E M1-E 2x 34 MCA left 1 N N N 56 - ICA-E, M1-E 35 MCA right 10 N N Y 84 ICA-E - Supplemental Table 1 . Details of the 35 non-IAT patients including the number and location of the detected foci of contrast enhancement (by AK).C: concentric. E: eccentric. ICA: (distal intracranial) internal carotid artery. M: segment of the middle cerebral artery (M1 and M2). NIHSS: National Institutes of Health Stroke Scale. Alteplase: recombinant tissue-type plasminogen activator.